Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results From a National Survey of Adults With Psoriasis in the United States

Teri Greiling,¹ Melodie Young,² Robert C. Higham,³ April Armstrong⁴


¹Department of Dermatology, Oregon Health & Science University, Portland, OR, USA; ²Mindful Dermatology, Modern Research Associates, Dallas, TX, USA; ³Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA; ⁴Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

INTRODUCTION

- Psoriasis affects about 3% of adults,¹ with prevalence of intertriginous involvement estimated at 3.2%–36%²
- A survey was conducted by the Harris Poll in the U.S. to understand the perspectives and burden of patients with plaque psoriasis (PsO) who use topical treatments to manage their disease
- This poster presents results from the subset of patients with psoriasis involvement in intertriginous areas

METHODS

• The survey was conducted online October 21 through November 24, 2021, among 507 U.S. adults aged 18+ years diagnosed with psoriasis by a healthcare provider (Figure 1)



OTC: 2.3 Prescription oral: 0.9



Treatment type preferred Topical: 70% Pills: 26% Injections: 4%

OTC: over the counter; PsO: plaque psoriasis. Patients with intertriginous area psoriasis, n=320.


Symptom severity


Mild: 20%

Moderate: 67%

Severe: 13%

- Participants had to use a topical treatment and not use a prescription injectable treatment for their psoriasis
- Response percentages were adjusted using a propensity score variable to adjust for respondents' propensity to be online and a model using ranked weights and Random Iterative Method weighting
- Patients with psoriasis in intertriginous areas were those who reported exhibiting symptoms in intertriginous areas when presented with a list of areas of the body or when aided with pictures in this area (Figure 2)
- 10% of patients overall reported having genital psoriasis, but genital involvement is not included in the intertriginous assessment





PsO: plaque psoriasis.

RESULTS

- Intertriginous Area
- commonly affected

- Stomach fold
- Under breasts


 - Armpits

Between buttocks

Patient-Reported Psoriasis Signs and Symptoms in the


• Of the 507 respondents, 320 (64%) patients with PsO reported having had symptoms in intertriginous areas during the course of their disease, with between buttocks and armpits being the most

• 40% of patients with psoriasis intertriginous area involvement did not report their PsO involved intertriginous areas until after they saw pictures of PsO in these areas (**Figure 3**)




Patient-Reported Burden of Intertriginous Psoriasis

- PsO in intertriginous areas has a negative impact on patients' lives, particularly their emotional well-being and their sex lives
- In the subset of patients with intertriginous psoriasis (n=320)
- Patients with PsO in intertriginous areas reported that it makes them feel embarrassed (80%), anxious (79%), or depressed (69%)
- Reported rates of emotional impact were numerically higher in patients with groin involvement (Figure 4)




- Intertriginous area PsO (n=320) particularly impacts patients' intimate and sexual relationships
- Patients reported intertriginous PsO having a very strong or strong negative impact on sexual distress/anxiety (45%), intimate relationships (39%), and sexual function (37%; Figure 5)
- Patients with groin involvement reported numerically higher rates of impact



- Nearly all participants (97%) say their intertriginous PsO has some effect on their overall quality of life, and most (66%) say this impact is slightly or moderately negative (Figure 6)
- Patients reporting a "very strong negative impact" on their quality of life was numerically higher in patients with groin involvement (16%) versus no groin involvement (6%) and in females (15%) versus males (6%)


Figure 5. Patient-Reported Very Strong/Strong Negative

Figure 6. Level of Negative Impact of Psoriasis in Intertriginous Areas on Overall Quality of Life



• Symptoms that cause the largest negative effects on the quality of life of those with PsO in intertriginous areas are itching (61%), scaling (53%), redness (49%), and skin cracking (46%) (Figure 7)


Figure 7. Patients' Psoriasis Signs and Symptoms Negatively Impacting Quality of Life



Patients' Perspective on Healthcare Provider (HCP) Visits


- Typical patient visits with HCPs about PsO vary, with some patients disrobing and others remaining fully clothed
- Although 70% of patients with intertriginous area involvement showed their psoriasis to HCPs, the most common area of intertriginous involvement was least likely to be shown to an HCP
- Of patients reporting intertriginous involvement, between the buttocks was the most common area (47%)
- Yet only 19% of patients showed this area of their body to their HCPs (Figure 8)

Figure 8. Most Common Intertriginous Areas Shown to HCPs



HCP: healthcare provider; PsO: plaque psoriasis.

Figure 9. Treatment Patterns and Preferences of Patients With Intertriginous Involvement



^aPatients with intertriginous plaque psoriasis (PsO; n=320); patients with intertriginous PsO using multiple treatments for different body areas (n=168).

CONCLUSIONS

- Almost 2 in 3 patients with PsO reported symptoms in intertriginous areas at some point in the course of their disease
- PsO in intertriginous areas has a negative impact on patients' lives, particularly their emotional well-being and their sexual health
- Typical protocols for HCP visits seem to range from some patients disrobing, whereas others remained fully clothed
- Intertriginous areas where patients are most likely to exhibit symptoms are also the areas that they are least likely to show an HCP
- Most patients with PsO in intertriginous areas who are using different topical treatments for different parts of their body feel that the ability to use a single treatment would be beneficial and increase adherence (Figure 9)

REFERENCES

- 1. Armstrong AW, et al. JAMA Dermatol 2021;157:940–946.
- 2. Dopytalska K, et al. *Reumatologia* 2018;56:392–398.

DISCLOSURES

AA is an investigator and consultant for Arcutis Biotherapeutics, Inc. and received grants/research funding and/or honoraria; **RCH** is an employee of Arcutis Biotherapeutics, Inc. Additional disclosures can be provided on request.

ACKNOWLEDGEMENTS

- This study was supported by Arcutis Biotherapeutics, Inc.
- Thank you to the investigators and their staff for their participation in the trial.
- We are grateful to the study participants and their families for their time and commitment.
- Writing support was provided by Lauren Ramsey, PharmD, Alligent Biopharm Consulting, LLC, and funded by Arcutis Biotherapeutics, Inc.